MediciNova Inc - Company Profile
Powered by 
All the sales intelligence you need on MediciNova Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how MediciNova Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with MediciNova Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
MediciNova Inc (MediciNova) develops innovative therapeutics for serious diseases with unmet medical needs. The company's strategic pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine), and MN-029 (denibulin), targeting a range of neurological, fibrotic, respiratory, and oncological disorders.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
MediciNova is dedicated to developing innovative therapeutics primarily targeting neurology, respiratory, and liver diseases where there are significant unmet medical needs. The company is engaged in the development of novel therapeutic compounds, focusing on MN-166 (ibudilast) and MN-001 (tipelukast). MN-166 is being developed as a non-opioid treatment for drug addiction, progressive multiple sclerosis, and pain, with its mechanism involving the suppression of pro-inflammatory cytokines and attenuation of neuroinflammation. MN-001 is being explored for its anti-fibrotic and anti-inflammatory properties, targeting conditions such as nonalcoholic fatty liver disease, idiopathic pulmonary fibrosis, and asthma. The company is also investigating MN-221 for acute exacerbations of asthma and COPD. As of December 2024, the company held 40 issued US patents and has filed four additional US patent applications. Additionally, MediciNova holds 124 issued foreign patents and 26 pending foreign patent applications corresponding to its US patents and patent applications. In FY2024, the company invested US$7.2 million on its R&D activities, which grew 27.2% YoY.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer